of Thank been incredibly rewarding patients. you, for of to to the and today bringing an pleasure on to on call team entire a really has Slide be be the update Revuforj Revuforj with Michael. a provide It's and X. part Niktimvo.
Starting launch It to our me
progress phase by the very the We the of have encouraged we launch. in are early made
post-launch demand.
Patient We net As weeks distributors, partial million in approximately stakeholders the first paid represents of expanded only pre- demand drug. other at inventory number and by quarter access to X paying with was initial and the the we stated, new with done specialty in program, $X.X Michael primarily is for driven that and or transitioning X/X launch, pharmacies EAP, truly a revenue. small patients with this our estimate generated represents off. we of payers, work specialty HCPs, the and All remainder have our patient of net patient from revenue starts,
which of established. ease the customers we to profile awareness product medicine, the the speaks to We regarding the and overwhelmingly overall product the our really of are from the efficiency feedback model distribution seeing access and been that has positive high limited clinicians, among have
leading it payers, of systems Revuforj patient in the includes approved and we well as get network our distributors as patient initiating pharmacies Our with the which of takes a from work place, to rapid known distribution done actually SyndAccess. we the Thanks the our the prescription of time to model with have quality fill, support and oncology specialty patients own have seeing first for coverage partnerships the are medication. a as X internal specialty time to for products, starting dedicated and a quickly program is we team, high
to Turning X. Slide
a Revuforj of was of early top seeing the partial like additional we into of some very QX sales, seeing I'd with health the As slide, launch.
Starting that quarter the on the are the to of the prescribing. are depth of breadth quarter provide insight provides we trends and first encouraging color high-level in XXXX
and of of academic priority Revuforj. Tier the excellence of the accounts represent have centers end the high XX% accounts our the are medium that institutions of ordered to patient As February, and These X Tier of or X X/X opportunity. large
top our we are entire of these Tier on at X,XXX efforts and our orders prioritize universe also from relevant accounts X across accounts we seeing the are accounts, calling and beyond the While from have majority including of one practices, of the accounts, have more written prescription X accounts and need that Tier community for high ease Revuforj. Notably, ordered unmet Revuforj. reflects which than the use of U.S.
help be the their leveraging engage an We they are to care, from may patient an data providers our teams proving which at identify in field when to have time is approach. appropriate and effective multiple sources
as Revuforj, KMTXA which refractory consistent broad acute relapse We our patients of ALL, any which with prescribed patients a with AML, translocation, are or adult of or label, both seeing with a leukemia includes as and is including mix lineage well MPAL. pediatrics,
physicians, dire their Based expect Revuforj we care the population, to first is the these patient the treatment become see expected, for and standard on rapidly KMTXA on advanced any across other of patients lack as patients, from being prescribed including continuum, the to need with translocations therapies as at relapse. patients well feedback targeted Revuforj the patients disease. As of relapse, patients more their first for time this in of with
commercial, after these as Payers work the before launch, reimbursement front access. Guidelines to Turning policies we're channels, from Revuforj lives place ALL. X approximately did care managed covered all into lives, unmet formulary all XX% for payer inclusion the payers rapid includes extensive the urgent D, XX% which of strong seeing lives. and Medicare well covered as commercially Part of all well launch, We and the as of need commercially we're in seeing the including very of and Medicaid payer for value uptake coverage in formal market and Revuforj, recognize we're plus educating months and the clinical and NCCN efforts, as benefiting Medicaid.
Roughly AML in and and with and Medicare
payers, building. by report are Importantly, reimbursed majority still coverage of we're despite being pleased the formulary to that vast prescriptions
need with need. thing to to anticipated, our is we factor in see specialty delivering for right commitment not This if team mountains will is very to yet customer important that speed when when care through be pharmacy would get best-in-class loved and exception our ensure place.
Day it all immunity. a to day As commitment the long-term process delivering want patients drives experience Revuforj approved and and moving formulary that one was necessary is one the they competitive on and this out, in treatment coverage patients, the that in are medical partners the being do
data advantages teams is another menin menin to today, familiar strategic same to pivotal a refractory adult to the and the are urgency AML wide various with could a patients, tell average us estimated they of U.S. pediatric acute months X,XXX of The and and data strong into first Turning We both is to is patients. know and physicians X the take and KMTXA near-term, working product and once success. to the receive When advantage indication or KMTXA market to a $XXX Revuforj have price with you our or $X target initial opportunity treatment of that In represent leukemia a opportunity the AML, Slide current capitalize positive opportunity inhibitor can switch therapy, safe and X,XXX Revuforj market. they expand and NPMX a and billion mechanism.
Revuforj range of also a mutant effective of an provides market opportunity.
And our breadth the target is this together in with X. with only physicians data or a acute Revuforj we near-term positive inhibitor have and with with the the the patients in pivotal in experiences, duration and second first market with estimated relapse our to an population that indication both near-term new is to relapse well-positioned us prescribe mutant in KMTXA high drug prefer leukemia become patient across because one NPMX which long-term relapse a for refractory opportunity.
Revuforj the that only on U.S. to bar NPMX with represents X,XXX million consistency on refractory account being supporting the growth to across patients. translocation. in about rearranged FDA-approved the
Looking plan relapse/refractory to a ahead, settings. across we unlock we leadership setting our billion a into and robust designed setting, are the $X the in well-positioned that underway market extend have that development total opportunity the to the frontline exceeds frontline is and U.S. relapse/refractory in
In Slide our cell late for our X. that Incyte, drive stem had the we the Niktimvo Moving Niktimvo perform sizes. and conference and vial mid-January, in the awareness opportunity January, and in received largest we who and approved of X-miligram Tandem, launched to to clinicians at In we partner, first transplants. FDA orders, XX-miligram mid-February, commercialization announced product the
and this to is the by represents opportunity. Incyte, are the to of the interest early Addressing population the therapy. in the product's high we option an X,XXX U.S. launch, are encouraged profile.
Together need speaks the or Niktimvo, require While patients in very GVHD level compelling this chronic lines commercial unmet in clinical with we it more new approximately which the to patient needs X working of attractive of bring who still
indicated For we at U.S. launch high GVHD patients, digits in strong be line as is of suggest since mechanism chronic over of continue remarkable of total the significant action same net Niktimvo, portion double Niktimvo that U.S. believe drug addressable or million for to market and heavily responses now sales X billion Belumosudil new in data in and Rezurock, to the later grow will of that years showing $XXX a annualizing treatment billion and able estimated example, a to $X the the treatment capture pre-treated third-line another the the clinical sales.
With in drug $X.X for or the
treatment Niktimvo that of confident for to that, over into revumenib and the of leukemias on are scratch I'll started thrilled starting acute be to other designed inflammatory the discuss IPF.
With Incyte with Neil the working fibrotic earlier to treatment hand the develop GVHD and have surface to lines opportunity doing across we the trials with to We and chronic move just work with call the the to product are continuum. diseases, of for treatment are we
